CN116637097A - Application of allicin in improving skeletal muscle disorder - Google Patents

Application of allicin in improving skeletal muscle disorder Download PDF

Info

Publication number
CN116637097A
CN116637097A CN202310897296.0A CN202310897296A CN116637097A CN 116637097 A CN116637097 A CN 116637097A CN 202310897296 A CN202310897296 A CN 202310897296A CN 116637097 A CN116637097 A CN 116637097A
Authority
CN
China
Prior art keywords
allicin
prdx5
skeletal muscle
cell
muscle disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310897296.0A
Other languages
Chinese (zh)
Inventor
沈胜楠
谷丽维
张珺哲
张昕炜
朱永平
刘艳青
郭秋岩
王继刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS
Original Assignee
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS filed Critical Institute of Materia Medica of CAMS
Priority to CN202310897296.0A priority Critical patent/CN116637097A/en
Publication of CN116637097A publication Critical patent/CN116637097A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the field of biotechnology, in particular to application of allicin in improving skeletal muscle disorder, and discovers that the allicin can obviously improve cell survival rate, reduce ROS content and H 2 O 2 The content improves the cell oxidative damage caused by TBHP, reconstructs the oxidative balance steady state, clarifies the stability of the allicin in the PRDX5, suggests that the PRDX5 is a specific target protein of the allicin, and Cys100 is a main binding site of the allicin and the PRDX5, and provides experimental basis for further popularization and application of the allicin in improving oxidative stress state and skeletal muscle disorder.

Description

Application of allicin in improving skeletal muscle disorder
Technical Field
The invention relates to the field of biotechnology, in particular to application of allicin in improving skeletal muscle disorder.
Background
Skeletal muscle is the largest organ of the human body, accounting for 40% of the total mass in adults, whose primary function is to generate mechanical forces to support body posture and promote various movements, and plays a key role in glycemic control and metabolic homeostasis. Studies have shown that a variety of disease states, such as aging, obesity, cachexia, etc., cause significant physiological changes in skeletal muscle, including a decrease in muscle strength, myogenesis rate, and an increase in muscle fatigue, ultimately leading to decline in skeletal muscle function such as insulin resistance, muscle atrophy, etc.
Mitochondrial dysfunction due to oxidative damage is a recognized primary causative agent of skeletal muscle dysfunction. The Peroxiredoxins (Prdxs) family of peroxidases has a highly conserved cysteine dependence and has been of great interest in scavenging peroxides, improving oxidative stress, and maintaining redox balance. Among the 6 subtypes of Prdxs family, PRDX5 exists mainly in mitochondria and cytoplasm, is a key hydrogen peroxide scavenging enzyme, and research shows that the overexpression of PRDX5 can directly reduce the generation of ROS, and forms an antioxidant system of mitochondria together with SOD2, TRX and PRDX 3. PRDX5 may also co-act with other factors, SIRT1 promoting expression of PRDX5 by interacting with FOXO3a and PGC-1 a, while modulating expression of other antioxidant enzymes. In addition, PRDX5 can interact with proteins such as NRF2, SIRT2-P53, STAT3 and the like to initiate signal transduction and corresponding biological effects.
Allicin is a bioactive substance extracted from garlic bulb of Liliaceae, its chemical name is diallyl trisulfide, and a large number of researches prove that allicin has various pharmacological effects of resisting apoptosis, preventing cardiovascular diseases, resisting aging, improving immunity, etc.
At present, allicin is studied for improving oxidative stress, but less in the skeletal muscle field. In conclusion, PRDX5 is taken as a target protein, and has broad prospect on diseases related to skeletal muscle dysfunction. The specific action mechanism of the allicin is unknown aiming at the further development of the pharmacological activity of the allicin, and the target protein is still to be elucidated. However, there is currently no report of improving skeletal muscle dysfunction by allicin targeting PRDX5.
Disclosure of Invention
The invention aims to improve skeletal muscle dysfunction, clarify the action targets and provide experimental basis for further popularization and application in subsequent drug and product development.
In a first aspect the invention provides the use of allicin for improving skeletal muscle disorders.
In some embodiments, the skeletal muscle disorder is a skeletal muscle disorder caused by oxidative damage.
In some embodiments, the allicin is at least one of allicin, or a garlic metabolite.
In some embodiments, the allicin targets PRDX5.
In some embodiments, the allicin is bound to PRDX5 at a stoichiometric 1:1 ratio.
In a second aspect the invention provides the use of allicin in the manufacture of a medicament and/or dietary supplement for the prevention and treatment of skeletal muscle disorders.
In some embodiments, the allicin is present at an effective concentration of 25-100 μm.
In a third aspect, the invention provides a pharmaceutical composition comprising allicin and a pharmaceutically acceptable carrier.
In some embodiments, the dosage form of the medicament comprises a tablet, capsule, oral liquid, oral granule, or oral powder.
In some embodiments, the allicin is the only active ingredient or one of the active ingredients.
Compared with the prior art, the invention has the following beneficial effects:
1. the invention discovers that the allicin can obviously improve the cell survival rate,Reducing ROS content and H 2 O 2 The content improves the cell oxidative damage caused by TBHP and rebuilds the oxidative balance steady state.
2. According to the invention, a large number of experiments prove that the stability of the allicin can be enhanced, and the PRDX5 is a specific target protein of the allicin, so that an experimental basis is provided for further popularization and application of the allicin in improving oxidative stress and skeletal muscle disorder.
3. The present invention further found that Cys100 is the primary binding site for allicin and PRDX5.
Drawings
FIG. 1 shows the cell viability (FIG. 1A), ROS content (FIG. 1B), and cell H of the C2C12 myotube cells of example 1 2 O 2 Content (fig. 1C) graph.
FIG. 2 shows Western blot detection of C2C12 cell differentiation regulatory factors (MyoD, myogenin, muRF-1, atrogin 1) in example 2;
FIG. 3 is a graph showing ROS content, H2O2 content (FIG. 3B) in model, control, and dosing groups of the PRDX5 silenced C2C12 cell line of example 3 (FIG. 3A);
FIG. 4A is a graph of the experimental results of example 4 on ITC, the upper graph showing the thermodynamic effect titration curve of the interaction of PRDX5 with allicin, and the lower graph showing the parameters of the model of PRDX5 binding to allicin; FIG. 4B is a graph of CETSA experiment results of example 5, wherein the upper graph shows the relative expression level of PRDX5 detected by western-blot at 37-73 ℃, and the lower graph shows the thermal melting curve of PRDX5 protein;
FIG. 5A is a graph of the results of the molecular docking experiments of example 6, and FIG. 5B is a graph of the effect of allicin on ROS content in a C2C12 point mutant cell line of example 7.
Detailed Description
The invention is based on the fact that allicin improves oxidative stress and improves skeletal muscle dysfunction to clarify an action target, and combines virtual screening and experimental verification, and discovers that PRDX5 is the action target of allicin which plays pharmacological activity for the first time, and the allicin activates PRDX5 to improve oxidative stress state and improve skeletal muscle dysfunction through cys100 of a cysteine binding site of the PRDX5, so that the allicin has positive treatment effect on related diseases caused by PRDX5 defects.
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
Establishment of a TBHP-induced C2C12 myotube cell oxidative damage model.
Obtaining cells: growing good-growth C2C12 myoblasts in DMEM medium containing 10% fetal calf serum, and placing at 37deg.C and 5% CO 2 Culturing in a constant-temperature closed incubator with saturated humidity, after cells were confluent at 70-80%, digested with 0.05% trypsin at 37℃and 10% 5 The individual/well cell density was inoculated into 96 well plates, and after 70-80% of the cells were fused, they were replaced with DMEM cell induction medium containing 2% horse serum, cultured for 4 days, and differentiated into myotube cells, which were grouped.
And (3) drug administration molding treatment:
a: blank control group: adding serum-free culture medium DMEM for culturing 24 h;
b: group of individual doses: adding serum-free culture medium DMEM containing allicin (100 μm) for culturing 24 h;
c: model group: 200. mu M TBHP treated cells for 6h, and then replaced by serum-free culture medium DMEM for 24 h;
drug administration group: 200. mu M TBHP treated cells for 6h, and then replaced with serum-free medium DMEM containing allicin at different concentrations for 24 h, (groups D, E and F, with allicin concentrations of 25. Mu.M, 50. Mu.M and 100. Mu.M respectively);
all the cells were placed at 37℃with 5% CO 2 Culturing in a constant temperature closed incubator with saturated humidity.
Detection of CCK-8 of model, control, and dosing group C2C12 myotube cells cell viability, 90 μl of culture broth and 10 μl of CCK-8 reagent (CCK 8, bi yun, C0038) were added to each well, and after incubation of 1.5. 1.5 h in the cell incubator, absorbance values (a 450) were measured with a fluorescent microplate reader at a wavelength of 450 nm according to the formula:cell viability (%) = cell viability was calculated for treatment group a 450/control group a450 x 100%. ROS content detection (reactive oxygen species detection kit, bi yun tian, S0033S): 1 mL of a medium containing DCFH-DA probe at a concentration of 10. Mu.M was added to each well, and after incubation at 37℃for 20 min, quantitative analysis was performed using a flow cytometer to detect the ROS content. Cell H 2 O 2 Content detection: (Hydrogen peroxide detection kit, biyundian, C0038), operating according to the reagent instructions, measuring absorbance value (A560) with a fluorescent microplate reader at a wavelength of 560 nm, calculating H using a standard curve based on protein concentration 2 O 2 Horizontal.
Experimental results referring to fig. 1, TBHP in the model group resulted in decreased C2C12 myotube cell viability (fig. 1A), ROS content (fig. 1B) and H compared to the control group 2 O 2 The content is increased (figure 1C), and allicin with different concentrations can remarkably improve the cell survival rate, reduce the ROS content and H 2 O 2 The content improves the cell oxidative damage caused by TBHP and rebuilds the oxidative balance steady state.
Example 2
Establishment of a model of TBHP-induced oxidative damage to C2C12 myotube cells was performed as in example 1. The cells were lysed using protein lysates, and the A-F group protein lysates were collected, followed by Western blot detection of C2C12 cell differentiation regulatory factors (MyoD, myogenin, muRF-1, atrogin 1) to evaluate C2C12 myoblast injury related factors.
Referring to fig. 2, compared with the blank control group (group a), TBHP in the model group (group C) causes C2C12 myotube cell injury, thereby affecting skeletal muscle function, inhibiting the expression of skeletal muscle differentiation regulation related factor MyoD, myogenin, promoting the expression of myoprotein degradation related factors MuRF-1 and atrogin1, and simultaneously, allicin with different concentrations can significantly promote the expression level of MyoD, myogenin, inhibit the expression of MuRF-1 and atrogin1, improve skeletal muscle injury caused by TBHP, and reestablish oxidative balance steady state.
The above results indicate that allicin may be able to improve skeletal muscle cell oxidative stress conditions in a dose-dependent manner including increasing cell survival, decreasing ROS content and H 2 O 2 Content, reestablishing oxidation balance steady state; downregulation of skeletal muscle related proteins by oxidative damage at all times improves skeletal muscle function.
Example 3
Constructing a PRDX5 gene silencing expression C2C12 cell line by utilizing a si-RNA technology: C2C12 was inoculated into 6-well plates as cells, respectively, and after 24 hours, the cells were divided into a negative control group (scrambled group (sc-37007, santa Cruz) and a siRNA interference technique silencing PRDX5 group (si-Prdx5Group, (sense: GCUACCCAGAUAACUUUCUTT; anti: AGAAAGUUAUCUGGGUAGCTT) (# 1080, santa Cruz)), cells were transfected with Lipofectamine3000 (Invitrogen), 80 nM siRNA per 6-well plate, and after 6h of transfection, the medium was changed to continue culture, and subsequent experiments were performed after cell differentiation was complete. Cell culture and establishment of a model of TBHP-induced oxidative damage to C2C12 myotube cells were performed as in example 1.si-Prdx5The components are a model group and an administration group. The scrambled component is a model building block and a dosing block. Model group: 200. mu M TBHP treated cells for 6h, and then replaced by serum-free culture medium DMEM for 24 h; drug administration group: 200. mu M TBHP treated cells for 6h, and then replaced with serum-free medium DMEM containing 100 mu M allicin for 24 h; control group: serum-free medium DMEM was cultured for 24 h. All the cells were placed at 37℃with 5% CO 2 Culturing in a constant temperature closed incubator with saturated humidity. To detect cellular ROS and H 2 O 2 The content was the same as in example 1.
Experimental results indicate that allicin cell protective activity is greatly reduced, and allicin cannot be purified by promoting ROS (FIG. 3A) and H 2 O 2 To enhance the resistance of the cells to oxidative damage (fig. 3B).
Example 4
CETSA-WB：
Cytothermal transition analysis (CETSA) explored the binding affinity of allicin to PRDX 5: differentiated and mature C2C12 myotube cells were cultured in a culture dish with a diameter of 10cm, and after the differentiation of the cells was completed, the specific culture method was the same as in example 1, and the cells were grouped: the control group: serum-free medium DMEM; drug administration group: adding 100 μm allicin, placing cells at 37deg.C, and 5% CO 2 Constant temperature of saturated humidityCulturing in a closed incubator for 24 hours, and then digesting with pancreatin to collect cells. Cells were suspended in 50mM HEPES lysis buffer, and after repeated freeze thawing for 3 times, they were mechanically sheared with a needle to lyse proteins. Collecting soluble proteins, equally dividing the soluble proteins into 10 PCR tubes, and respectively carrying out heat treatment at different temperatures of 37-73 ℃ for 3 minutes to collect the soluble proteins; the method is used for subsequent Western blot detection and is used for confirming that allicin is combined with PRDX5 under different temperature treatment conditions and forms a heat-stable protein complex.
CETSA-WB experimental results show that allicin can enhance the stability of PRDX5, suggesting that PRDX5 is a specific target protein of allicin (FIG. 4A).
Example 5
Isothermal titration calorimetry ITC method analysis of allicin affinity assay for PRDX5 protein:
purifying PRDX5 protein, diluting the PRDX5 protein solution to 200 mu M with PBS, and taking 200 mu L of the solution into a centrifuge tube; garlicin PBS solution was taken at a concentration of 200. Mu.M and an experimental volume of 60. Mu.L. ITC detection was performed at constant temperature of 25 ℃. The rotation speed is 750 r/min, 13 drops are titrated together, and the interval is 150 s. The remaining 12 drops were 2. Mu.L in volume except for the first drop of 0.4. Mu.L. Each result was processed using ITC Analysis software and KD and related thermodynamic constants were fitted by subtracting the background signal.
ITC experimental results showed that allicin bound to PRDX5 at a stoichiometric 1:1 ratio, KD value of 1.08±0.30 μm, Δg= -8.51 kcal/mol, -tΔs= -15.4 kcal/mol, Δh= -80 kcal/mol, indicating that allicin and PRDX5 may interact through hydrogen bonding and electrostatic interactions (fig. 4B).
Example 6
To further explore the mode of action of allicin with PRDX5, a molecular docking experiment was used to prepare a PRDX5 structural file (PDB ID: 3 MNG), and in AutoDock's visualization tool Python Molecular Viewer (PMV), the ligand and receptor files were converted to pdbqt format using ADT tools. During ligand conversion, all of the hydrogen on the ligand needs to be added to ensure that the Gasteiger charge is calculated correctly. The rotatable bond of the ligand was detected and set up in the ADT tool using a Torsion Tree. In the PRDX5 conversion process, the file format is saved after hydrogenation. And importing the PRDX5 in the pdbqt format, setting the size and the center position of a Grid in a Grid module of the ADT by using a Grid box tool, obtaining gpf parameter files after setting, operating autoprid 4, obtaining glg Grid point energy recording files and recording map files of a series of acting forces such as electrostatic force, van der Waals force and the like after calculation. Setting search parameters in the ADT module, setting 100 docking generating conformations by using a Ramahk genetic algorithm, storing dpf docking parameter files, and operating autodock4 to obtain dlg docking record files.
Experimental results indicate that the binding pocket of allicin and PRDX5 is very identical and conformationally stable, involving hydrogen bonding and hydrophobic interactions, wherein Cys100 is the primary binding site for allicin and PRDX5 (fig. 5A).
Example 7
PRDX5 overexpression and establishment of a point mutant C2C12 cell line. Functional amino acid identified by molecular butt joint is used as mutation site, and in order to further explore the interaction mode of allicin and PRDX5, an over-expression cell line of PRDX5 wild type (PRDX 5-WT, amino acid sequence is shown as SEQ ID NO. 1) and the mutation of Cys100 amino acid residue in PRDX5 into Ala (PRDX 5-C100A, amino acid sequence is shown as SEQ ID NO. 2) is respectively constructed. One-step PCR was performed to amplify the target gene of the mutant, after confirming the mutant, pSFFV. Neo vectors linking PRDX5 to different mutants were transferred into C2C12 cells by electroporation transfection, and G418 was used to select cell lines stably expressing PRDX5 and mutants thereof. The overexpressed C2C12 cells were seeded into 6-well plates, respectively, and were divided into PRDX5 wild-type overexpressing cell line control (PRDX 5-WT) and PRDX5 mutant (PRDX 5 OV-C100A) groups, followed by cell culture as in example 1. The PRDX5-WT component was a model group and an administration group. The PRDX5OV-C100A composition was used as a model and drug administration composition in the same manner as in example 4.
According to molecular docking experimental results, a point mutation cell line is constructed, and experimental results show that Cys100 mutation leads allicin not to exert cytoprotective activity by promoting ROS clearance (figure 5B), and that Cys100 amino acid residues are critical to interaction of allicin and PRDX5, and Cys100 in PRDX5 can be selectively combined through hydrophobic interaction, so that the antioxidant activity of the allicin can be enhanced.
While the foregoing is directed to the preferred embodiments of the present invention, it will be appreciated by those skilled in the art that various modifications and adaptations can be made without departing from the principles of the present invention, and such modifications and adaptations are intended to be comprehended within the scope of the present invention.

Claims (10)

1. Use of allicin for improving skeletal muscle disorders.
2. The use according to claim 1, wherein the skeletal muscle disorder is a skeletal muscle disorder caused by oxidative damage.
3. The use according to claim 1, wherein the allicin is at least one of allicin, allicin or a garlic metabolite.
4. The use according to claim 1, wherein the allicin targets PRDX5.
5. The use of claim 4, wherein the allicin is bound to PRDX5 in a stoichiometric 1:1 ratio.
6. Use of allicin in the preparation of a medicament and/or dietary supplement for the prevention and treatment of skeletal muscle disorders.
7. The use according to claim 6, wherein the allicin has an action concentration of 25-100 μm.
8. A pharmaceutical composition comprising allicin and a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 8, wherein the dosage form of the drug comprises a tablet, a capsule, an oral liquid, an oral granule, or an oral powder.
10. The pharmaceutical composition of claim 9, wherein the allicin is the only active ingredient or one of the active ingredients.
CN202310897296.0A 2023-07-21 2023-07-21 Application of allicin in improving skeletal muscle disorder Pending CN116637097A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310897296.0A CN116637097A (en) 2023-07-21 2023-07-21 Application of allicin in improving skeletal muscle disorder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310897296.0A CN116637097A (en) 2023-07-21 2023-07-21 Application of allicin in improving skeletal muscle disorder

Publications (1)

Publication Number Publication Date
CN116637097A true CN116637097A (en) 2023-08-25

Family

ID=87625096

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310897296.0A Pending CN116637097A (en) 2023-07-21 2023-07-21 Application of allicin in improving skeletal muscle disorder

Country Status (1)

Country Link
CN (1) CN116637097A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190015470A1 (en) * 2016-01-08 2019-01-17 Inqpharm Group Sdn Bhd Garlic compositions
CN112972454A (en) * 2021-03-10 2021-06-18 上海交通大学医学院附属第九人民医院 Application of allicin in preparation of product for preventing or treating hereditary cardiomyopathy
RU2761618C1 (en) * 2021-03-24 2021-12-13 Федеральное государственное бюджетное образовательное учреждение высшего образования Астраханский государственный технический университет, ФГБОУ ВО «АГТУ» Tool improving the coordination of the musculoskeletal system of a person with 1st degree obesity
RU2769519C1 (en) * 2021-06-02 2022-04-01 Государственное автономное образовательное учреждение Астраханской области высшего образования "Астраханский государственный архитектурно-строительный университет" ГАОУ АО ВО "АГАСУ" Tool that improves the coordination of the musculoskeletal system of a person with 2nd degree obesity
US20220249590A1 (en) * 2021-02-10 2022-08-11 Naglaa Hussein Efficacy of garlic therapy in controlling inflammatory cytokines and cartilage degradation in knee osteoarthritis and improving quality of life

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190015470A1 (en) * 2016-01-08 2019-01-17 Inqpharm Group Sdn Bhd Garlic compositions
US20220249590A1 (en) * 2021-02-10 2022-08-11 Naglaa Hussein Efficacy of garlic therapy in controlling inflammatory cytokines and cartilage degradation in knee osteoarthritis and improving quality of life
CN112972454A (en) * 2021-03-10 2021-06-18 上海交通大学医学院附属第九人民医院 Application of allicin in preparation of product for preventing or treating hereditary cardiomyopathy
RU2761618C1 (en) * 2021-03-24 2021-12-13 Федеральное государственное бюджетное образовательное учреждение высшего образования Астраханский государственный технический университет, ФГБОУ ВО «АГТУ» Tool improving the coordination of the musculoskeletal system of a person with 1st degree obesity
RU2769519C1 (en) * 2021-06-02 2022-04-01 Государственное автономное образовательное учреждение Астраханской области высшего образования "Астраханский государственный архитектурно-строительный университет" ГАОУ АО ВО "АГАСУ" Tool that improves the coordination of the musculoskeletal system of a person with 2nd degree obesity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JI SOOK KANG等: "Antioxidative effects of diallyl trisulfide on hydrogen peroxide induced cytotoxicity through regulation of nuclear factor-E2-related factor-mediated thioredoxin reductase 1 expression in C2C12 skeletal muscle myoblast cells", GENERAL PHYSIOLOGY AND BIOPHYSICS, vol. 36, no. 2, pages 129 - 139 *
刘震超等: "药理研究方法学", vol. 1, 中国医药科学技术出版社, pages: 830 - 831 *

Similar Documents

Publication Publication Date Title
AU2023241400A1 (en) Novel crispr enzymes and systems
JP7015169B2 (en) Mammalian cells enriched with functional mitochondria
US20230287419A1 (en) DUCHENNE MUSCULAR DYSTROPHY-RELATED EXONIC SPLICING ENHANCER, sgRNA AND GENE EDITING TOOL, AND APPLICATIONS
US10668104B2 (en) Brown adipocyte modification
Widmer et al. Identification of a second human acetyl-CoA carboxylase gene
Hossain et al. Cancer suicide gene therapy with TK. 007
CN109415740A (en) Express the mescenchymal stem cell and application thereof of TRAIL and CD
CN109971787A (en) A kind of CYBB slow virus carrier, stem cell of slow virus carrier transfection and its preparation method and application
CN112143705B (en) Double-gene modified stem cell and application thereof
Sullivan et al. Ornithine-δ-aminotransferase expression and ornithine metabolism in cultured epidermal keratinocytes: toward metabolic sink therapy for gyrate atrophy
CN110423812B (en) Use of Skiv2l2 (MTR 4) gene in tumor treatment
CN116637097A (en) Application of allicin in improving skeletal muscle disorder
CN116693626A (en) Staple peptides and uses thereof and methods for expanding stem cells in vitro
CN107899002B (en) Application of osteocalcin in regulation of endothelial progenitor cell exosomes
CN109337903A (en) Long-chain non-coding RNA lncRNA-6585, antibody and application thereof
Liu et al. Efficient therapeutic gene expression in cultured rat hippocampal neurons mediated by human foamy virus vectors: a potential for the treatment of neurological diseases
CN111944014B (en) Sea cucumber polypeptide and application thereof
Liu et al. Recombinant human foamy virus, a novel vector for neurological disorders gene therapy, drives production of GAD in cultured astrocytes
AU2021400745A1 (en) Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
CN111718891B (en) Application of circular RNA in regulation of pancreatic islet beta cell proliferation
CN113151182A (en) Preparation method and application of gene recombinant cell based on MSC
CN112023048A (en) Construction method and application of stable-transformation recombinant B lymphocyte leukemia cell line resistant to cytarabine
CN106075396B (en) The application of Cul4 albumen
CN111233996A (en) Method for promoting engineered cell strain to secrete and express rhIL-24 by using sodium butyrate
WO2018209801A1 (en) Application of ul43 protein in preparing drug for treating or preventing mitochondrial dysfunction

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination